Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells

Oncology Reports

Volumn 21, Issue 6, 2009, Pages 1405-1411

  Zhao, Wei Peng ^a   Zhu, Bo ^a   Duan, Yu Zhong ^a   Chen, Zheng Tang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Complement resistance; Heceptin; Lung carcinoma; Membrane complement regulatory proteins

Indexed keywords

CD55 ANTIBODY; CD59 ANTIBODY; CD59 ANTIGEN; CISPLATIN; DECAY ACCELERATING FACTOR; MONOCLONAL ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD59 PROTEIN, HUMAN;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOCARCINOMA; CELL SURVIVAL; DRUG EFFECT; IC 50; IMMUNOLOGY; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TIME; TUMOR CELL LINE; TUMOR ESCAPE;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD55; ANTIGENS, CD59; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; COMPLEMENT ACTIVATION; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MALE; MIDDLE AGED; TIME FACTORS; TUMOR ESCAPE;

EID: 67649987713     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000368     Document Type: Article

References (28)

1. Yuste L, Montero JC, Esparis-Ogando A, et al: Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. Cancer Res 65: 6801-6810, 2005.
2. Zinner RG, Kim J, Herbst RS, et al: Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer 37: 17-27, 2002.
3. Swanton C, Futreal A and Eisen T: Her2-targeted therapies in non-small cell lung cancer. Clin Cancer Res 12: S4377-S4383, 2006.
4. Kern JA, Torney L and Weiner D: Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody. Am J Respir Cell Mol Biol 9: 448-454, 1993.
5. Bunn PA, Helfrich B, Soriano AF, et al: Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res 7: 3239-3250, 2001.
6. Spiridon CI, Guinn S, Vitetta ES, et al: A Comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies. Clin Cancer Res 10: 3542-3551, 2004.
7. Nahta R and Esteva FJ: Herceptin: mechanisms of action and resistance. Cancer Lett 232: 123-138, 2006.
8. Tedesco F, Bulla R and Fischetti F: Terminal complement complex: regulation of formation and pathophysiological function. In: The Complement System: Novel Rules in Health and Disease. Szebeni J (ed). Kluwer Academic Publishers, Boston, pp97-127, 2004.
9. Garred P, Hetland G, Mollnes TE, et al: Synthesis of C3, C5, C6, C7, C8, and C9 by human fibroblasts. Scand J Immunol 32: 555-560, 1990.
10. Langeggen H, Paus M, Johnson E, et al: The endothelium is an extrahepatic site of synthesis of the seventh component of the complement system. Clin Exp Immunol 121: 69-76, 2000.
11. Shimo K, Mizuno M, Nasu J, et al: Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinoma. J Gastroenterol Hepatol 19: 643-647, 2004.
12. Gelderman KA, Blok VT, Fleuren GJ, et al: The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. Lab Invest 82: 483-493, 2002.
13. Madjd Z, Durrant LG, Pinder SE, et al: Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)? Cancer Immunol Immunother 54: 149-156, 2005.
14. Macor P, Tripodo C, Zorzet S, et al: In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 67: 10556-10563, 2007.
15. Hirsch FR, Franklin WA, Veve R, et al: Her2/neu expression in malignant lung tumors. Semin Oncol 29: 51-58, 2002.
16. Ziller F, Macor P, Bulla R, et al: Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur J Immunol 35: 2175-2183, 2005.
17. Reilly CA, Taylor JL, Lanza DL, et al: Capsaicinoids cause inflammation and epithelial cell death through activation of vanilloid receptors. Toxicol Sci 73: 170-181, 2003.
18. Jacobs SA and Foon KA: Monoclonal antibody therapy of leukaemias and lymphomas. Exp Opin Biol Ther 5: 1225-1243, 2005.
19. Baselga J and Tripathy D: Phase II study of weekly intravenous humanized antip185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol 14: 737-744, 1996.
20. Cerny T, Borisch B, Introna M, et al: Mechanism of action of rituximab. Anticancer Drugs 13 (Suppl. 2): S3-S10, 2002.
21. Gelderman K, Kuppen P, Okada N, et al: Tumor-specific inhibition of membrane-bound complement regulatory protein Crry with bispecific monoclonal antibodies prevents tumor outgrowth in a rat colorectal cancer lung metastases model. Cancer Res 64: 4366-4372, 2004.
22. Sier CF, Gelderman KA, Prins FA, et al: Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation. Int J Cancer 109: 900-908, 2004.
23. + T-cell epitopes nested in unique NH2-terminal VH sequence of antiidiotypic antibodies? Cancer Res 65: 6001-6004, 2005.
24. Treon SP, Mitsiades C, Mitsiades N, et al: Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. Immunotherapy 24: 263-271, 2001.
25. Bjorge L, Stoiber H, Dierich MP, et al: Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy. Scand J Immunol 63: 355-364, 2006.
26. Guo B, Ma ZW, Li H, et al: Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity. Clin Immunol 128: 155-163, 2008.
27. Zinner RG, Glisson BS, Fossella FV, et al: Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer 44: 99-110, 2004.
28. Tsurutani J, West KA, Sayyah J, et al: Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res 65: 8423-8432, 2005.